コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inhibitors and integrase inhibitors (without cobicistat).
2 ated with more weight gain than elvitegravir/cobicistat.
3 ated with more weight gain than elvitegravir/cobicistat.
4 , and 159 in those who received elvitegravir-cobicistat.
5 al rilpivirine, raltegravir, or elvitegravir-cobicistat.
7 xed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir a
8 ose oral formulation of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir a
9 ingle-tablet containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir a
10 system to open-label elvitegravir (150 mg), cobicistat (150 mg), emtricitabine (200 mg), and tenofov
11 arer) containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir al
12 blets containing 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir al
13 for raltegravir, and 89.8% for elvitegravir-cobicistat (adjusted risk differences vs. dolutegravir,
14 z (EFV) to rilpivirine (RPV) or elvitegravir/cobicistat and switch from tenofovir disoproxil fumarate
15 and we identify nelfinavir, rupintrivir, and cobicistat as the most selective inhibitors of SARS-CoV-
16 fumarate (DF) plus emtricitabine, and either cobicistat-boosted elvitegravir (EVGcobi), rilpivirine (
17 F) co-formulated with elvitegravir (EVG, E), cobicistat (C) and emtricitabine (F), a recommended anti
18 F) co-formulated with elvitegravir (EVG; E), cobicistat (C), and emtricitabine (F), a recommended ant
20 pharmacokinetic boosters ritonavir (RTV) or cobicistat (COBI) may be complicated by pharmacokinetic
21 been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir di
22 been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir di
23 emtricitabine (FTC), the quad pill includes cobicistat (COBI; an inactivator of cytochrome P450 isoe
24 e P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV patients as ph
25 le antiretroviral therapy with elvitegravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoprox
26 ing) to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group)
27 ants were randomly assigned to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (n=
28 ety and efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as
29 22 (20%) participants in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide gro
30 tween groups (four [4%] in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide gro
31 diarrhoea (eight [7%]) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide gro
33 ity was 2.24% (SD 3.27) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide gro
34 ensity was 1.33% (2.20) in the elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide gro
35 nofovir disoproxil fumarate to elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in
36 let, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in
37 let, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is
40 ing to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide ver
41 The fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was
43 e inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fuma
44 the initiation of therapy with elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fuma
45 omly assigned (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fuma
48 ther to switch to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir or to continue
52 oth formulations, combined with elvitegravir/cobicistat/emtricitabine, maintained HIV-1 RNA suppressi
53 DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA
54 DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TA
55 ecaprevir and pibrentasvir with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, abacavir
56 which compared the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (
57 ngs on the use of dolutegravir and darunavir/cobicistat for treatment of pregnant women living with h
58 nts either switched immediately to darunavir/cobicistat/FTC/TAF (D/C/F/TAF) or continued INSTI + TAF/
59 ancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus
61 raltegravir, dolutegravir, and elvitegravir-cobicistat) or efavirenz (EFV) as an active comparator,
62 port the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir con
64 etics, and efficacy of GSK2838232 boosted by cobicistat were evaluated in individuals with HIV-1 infe